At the 2016 American Association for Cancer Research annual meeting today, scientists presented their results of a follow-up study tracking the survival of metastatic melanoma… Read More »One-third of patients with metastatic melanoma treated with immunotherapy drug nivolumab survive five years
In today’s news, former President Jimmy Carter, who has metastatic melanoma, revealed that he has responded well to treatment. We asked melanoma expert Evan J.… Read More »Jimmy Carter Announces Cancer Scan Findings
This week, the FDA approved a new therapy called talimogene laherparepvec, which goes by the trade name, Imlygic, for the treatment of certain types of melanoma.… Read More »Melanoma drug FDA approved
***This post was written by Deb Stewart, R.N., who leads a group of Survivor Volunteers in the Johns Hopkins Breast Center. In honor of National… Read More »The True Value of Volunteering
Just as most patients have concerns and worries when treatment ends, many children also experience uncertainty and fear when a parent finishes treatment for breast… Read More »Cancer is a Family Matter: Six Tips to Help Your Kids Cope
Cancer headlines this past month included two studies on colonoscopy, a screening tool for colon cancer. The first study looks at the long-term benefits of… Read More »Cancer News Review
Researchers from the Vanderbilt-Ingram Cancer Center and other institutions reported more data today on studies of a new melanoma drug that target products of a… Read More »More Good News on Melanoma Drug
It's been a game-changing year in cancer research. Doctors and scientists don't typically like to use those words, but here's why I think this is a… Read More »Top Trends in Cancer Research 2011
On September 14, 2011, I was invited to a special premiere of the movie 50/50. A group of cancer care providers packed into a movie theater… Read More »Beating the Odds of Cancer with Humor: 50/50 Movie
Everyone has their own reason. For some, they feel grateful for how far they have come or to remember those they have lost. For others,… Read More »Part 4: Why I Walk